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ABSTRACT 
Objective: Diabetes is a serious illness. It is a key and growing threat to the health of the global world. The prime concern of this research was to 
estimate the cost-of-illness of type 2 diabetes in Karachi, a major metropolitan city of Pakistan. This study was performed on the basis a community 
perspective to calculate the economic burden of diabetes mellitus type 2 in Pakistan. 
Methods: This study was conducted in all districts of Karachi, the patients were taken from all economic segment of society from low income group, 
average revenue and high revenue group. A preliminary test questionnaire was used to collect the data directly from patients and in some locations 
conducted interviews with patients due to lack of understanding and un-educated patients. The total of 885diabetes patients was selected with 
convenient random sampling. 
Results: The average direct cost of all these expense bear by diabetic patient in Pakistan is Pak Rupees Rs.5542 per month. The cost range starts 
from Rs. 650/month to 20000 per month on the basis of patient economic condition and disease state. The average appointment fee of a physician, 
laboratory test and medicines came to Rs. 700/visit, 400/test, and 1100/visit precisely. The average travel and food spent was Rs.200/visit and 
1000/month. Medicine accounted for largest cost followed by consultation with the physician. 
Conclusion: This is clearly indicated by this study that considerable cost is amounted by diabetes, it is suggested that a huge amount of resources 
could be prevented by taking care, initial understanding of the disease and a decrease in diabetes co-morbidities and complications through better 
diabetes mellitus treatment. Very extensive and cost-effective programs should be started to maximize health benefits and to diminish the 
prevalence of this epidemic. 
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INTRODUCTION 
Diabetic mellitus type 2 is a widespread and persistent disease 
which displays undue burden on society [1]. Among types of 
diabetes mellitus the global prevalence of diabetes mellitus type 2 is 
approximately 100 million people which may exceed up to 300 
million in 2025 as reported by the forecast [2]. The probability of 
other diseases including cardiovascular disease, obesity, 
hypertension and dislipidemia become higher in patients suffering 
from diabetes mellitus type 2 [3]. 
These complications lower the scale of quality of life of patients as 
the ratio of morbidity and mortality increase [4] whereas society 
undergo in extreme burden due to health care cost [5, 6]. One of the 
studies conducted in 1998 in Europe reported three times more 
spending of healthcare facilities in the treatment of diabetes 
complications as compared to the onset of the disease before its 
complications [7]. Another study reported approximation about 
people mortality due to diabetes was 2.9 million [8]. Comparatively 
South Asia is found to be the place where diabetes is spreading more 
rapidly, the important countries of the said region comprises of 
India, Pakistan, Bangladesh, Nepal, Sri Lanka, Bhutan and Maldives 
where the predicted increase in diabetes from the year 2000 to 2030 
is 40% [9]. An assessment has done by IDF Diabetes Atlas [10] on 
the global spending for the prevention and treatment of diabetes 
and its adverse events will be exceed by 114 USD billion in 2030. 
The approximate calculation of worldwide health expenditure to 
stop and treat diabetes and its complication was at least 376 billion 
dollars (USD) in 2010. by 2030 this number exceeds 490 billion US 
dollar (USD). There is a huge inequality in health care expenditure 
on diabetes between regions and countries. Above 80% of the 
universal expenditure on diabetes are made in worlds’ economically 
richest countries not in the low and middle income countries where 
80% of people with diabetes will soon live [11].  
Diabetes is known to be the costly disease due to its chronic nature 
and complications. Internationally, the lowest predictable direct 
disbursement of diabetes among 20 to 79 years of age is $153 billion 
per annum. Premature death, patient disability due to diabetes 
causes loss of productivity which ultimately produced economic 
burden on society. There is the huge difference in the economic 
burden among patients living in different countries depending upon 
their financial status and policies implemented on them. Healthcare 
spending of families in Latin America is 40-60% while in India the 
mediocre patients pay out 25% of their whole earnings [12]. The 
estimated direct cost for the diabetic patient in Karachi was $197 
per year [13].  
We choose a study design of prevalence base “Cost of Illness" to find 
out the direct cost of treatment expenditure of diabetes mellitus in 
different 15 outpatient clinic setting at 5 different sites in Karachi, 
Pakistan. Karachi, consists of more than 15 million residents and is 
regard a superior and economic zone of Pakistan. At the foundation, 
economic burden of the disease show a specific economic procedure 
[13]. This study was conducted in 5 districts of Karachi. The study 
was carried out in 15 different outpatient clinics at 5 selected sites 
of five Karachi districts. The patients were selected from all socio 
economic segment of society from the low income group, average 
income and significant revenue earning class to avoid any business 
in selection. The diabetic patients were selected with the help of 
doctor diagnosis of the patient and the patient who are fulfilling the 
eligibility criteria were choosing by random sampling technique. 
From each setting two clinic diabetic managements, clinic/family 
practice/general medicine/internal medicine was selected.  
MATERIALS AND METHODS  
A format of precise pre test questionnaire was set to gain the 
information on socio-demographic and clinical individuality and in 
some locations conducted interviews with patients due to lack of 
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understanding and un-educated patients. The total of 900 diabetes 
patients was approached based on proportionate attendance of 
patient, with convenient random sampling. From all randomly 
selected individuals 885 were found willing to participate in the 
study Exclusive criteria consist of pregnant women, people having 
age of less than 20 years and those having an age of more than 60 
years relevant data regarding direct cost were obtained from the 
patients. We use pharmacy guide for the purpose of calculation of 
the cost of medicines. All costs were used in Pakistani Rupee; a rate 
of Rs 106 per US$ was used to represent costs in terms of 
international currency. 
Perspective 
Perspective signifies the type of cost to be included in the study. The 
societal perspective was taken to find out the direct cost of treatment.  
Ethical approval 
Ethical approval permission was ensured from the Board of Advance 
Study and Research (BASR) of the University of Karachi. Prior 
consent was taken from doctors and patients for this study. All 
educated patients read the permission paper. For the uneducated 
patients, the interviewer explain and teach the consent paper to 
them and if they show commitment and agreement, then taken the 
interview with the help of questionnaire. 
Data Analysis 
Data were authorized following double entry as given the code 
number of all filled questionnaire and then data was first input in 
the excel sheet and then analyzed further on SPSS, mean, variance, 
valid frequency of answer, percentage and cumulative percentage 
was taken. The histogram of data was taken for further 
understanding. The significance level is of 5%. The direct and 
indirect costs were taken from patients to calculate the total 
economic burden of the diabetes mellitus type 2. The costs for 
consultation and other diabetes management services were used the 
approximate average cost of different services in Karachi. 
RESULTS AND DISCUSSION  
Demographic and clinical properties 
Totally 885 individuals with diabetes were asked with a highest 
percentage of age group with more than 51 years of age is (51.5%). 
A Majority (53.7%) of study subjects were female and male was 
46.2% and of the total 33.1% individuals had graduation 
qualifications or having superior qualification. Of the total, less than 
Rs 15000 household income was 20.6%. More than Rs 45000 income 
range was 12.2% using NHSP criteria. Family histories of diabetes 
patients were recorded. The percentage of family history with diabetes 
was 58% and family history without diabetes was 41.5%. 
Direct cost of diabetes care 
The costs are based on answers of patients during interview and survey, 
then it confirm by Laboratories, Doctors feedback, Medicine cost refer by 
Drug Pharmaguide 2014. The average expense of appointments with a 
physician, laboratory examinations and medicines cost is up to Rs. 
700/visit, 400/test, 1100/visit sequentially. The average expense for 
travel and food acquire was Rs.200/visit and 1000/month, average 
expense is given in the following table. 
 
 
Fig. 1: Direct cost of Diabetes Mellitus Type patients in PKR per 
visit 
Table 1: Socio-Demographic characteristics of Diabetes Mellitus 
Type 2 patients of Karachi Pakistan (n=885) 
Characteristics Number of Patients Percentages % 
(Age) 
20 – 30 years 33 3.7 
31 – 40 years 90 10.1 
41 – 51 years 306 34.5 
51-60years 456 51.5 
(Sex) 
Male 406 46.2 
Female 476 53.7 
(Marital Status) 
Single 40 4.5 
Married 822 92.8 
Divorced 19 6.4 
Not Answer 4 0.4 
(Education) 
Primary 108 12.2 
Middle 51 5.7 
Secondary 136 15.3 
Inter 178 20.1 
Graduate 293 33.1 
Master 116 13.1 
Not Answer 3 0.3 
(Family History of Diabetes) 
Yes  514 58.0 
No 368 41.5 
Not Answer 3 0.3 
(Monthly Income) 
Less than 15000 183 20.6 
15000 – 30000 272 30.7 
31000 – 45000 201 22.7 
More than 45000 108 12.2 
Not Answer  120 13.5 
 
Table 2: Direct cost of Diabetes Mellitus Type 2 patients in 
Pakistani Rupee per visit 
Variables Average Cost in Rupees  
Direct Cost   
Consultation  700/ Visit 
Lab Test 400/Test 
Sugar level test at home 1000/ Month 
Medicine 1100/Month 
Travel Cost 200/Visit 
Syringes & Dispensing of Insulin 50/Day 
Others (Diabetic food) 1000/Month 
 
RESULTS AND DISCUSSION 
Diabetes mellitus is very expensive illness throughout the world and 
its expenditure affects most of the members of our society and 
government and private health institutions [13]. Diabetes mellitus is 
the main cause of expense of health care portion and lead to 
economic burden. The integrated Healthcare System has a set of 
actions to encourage health, prevention, diagnosis, management, 
professional training, monitoring and pharmaceutical care and 
services, and research for diabetes care [14]. Numerous socio-
economic factors and health care delivery associated issues 
influence the consequences of diabetes and as a result the expense 
and vice-versa [15]. The decision makers have to allocate resources 
effectively and efficiently. 
Key finding related to the cost have concluded from this study. This 
study help in better health planning and it indicates how much 
society is spending on the management of type 2 diabetic mellitus. 
Once the diabetes is developed then it is needed to control diabetes 
to avert the diabetes co-morbidity and complication which can again 
cause significant cost. It indicates the cost of diabetes, which can 
then be used for prevention of diabetes programs. This study 
identifies the divers’ component of the cost and magnitude of the 
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contribution of each cost. This research has been carried out using 
societal perspective, which is usually preferred for public health 
decisions. 
Total 885 individuals with diabetic mellitus were consulted for 
interview the questions were asked related to demography and 
socioeconomic status of the patients and related to consultation, 
laboratory test, sugar level test at home, medicine, travelling cost, 
syringes & dispensing of insulin and diabetic food. The study shows 
that averagely the individual person cost for diabetes is Rs.700 per 
visit on consultation, Rs.400 per lab test, Rs.1000/month on sugar 
level test at home, Rs.1100/month on medication Rs. 200/visit 
travel cost Rs.50/day on syringes & dispensing of insulin Rs. 
1000/month on diabetic food. Medicines consumed largest cost 
followed by laboratory examination, lab test and sugar level test at 
home). Same kind of results have founded in some other studies [16, 
17, 18], as well as in developing countries. 
This is finding out from this study that those patients with longer 
duration of treatment with diabetes with more complication and co 
morbidities bear high cost. Same kind of result has achieved from 
other studies perform in develop and none develop countries [19, 
20] recommended that complication is the key reason for increasing 
the cost of treatment in diabetic patients which will influence the 
healthcare system. The study is not for the purpose to find 
association of cost among demographic factor and diabetic mellitus 
management [21], studied the association between costs and 
demographical characteristics and clinical individuality in 1,371 
Dutch individual with diabetic mellitus using a statistical tool. 
It is concluded that independent associations exist between age, 
insulin use, presence of macro vascular complications, presence of 
micro vascular and macro vascular complications, hyperlipidemia, 
and expense. there is a difference between our study and this study 
in many ways. First demographic characteristics, management of 
diabetes were analyzed by questionnaire but not with the help of 
medical chart review.  
Second, costs were calculated as an average rather than 
multiplicative models. Third, we did not analyze the association 
among individual micro vascular and macro vascular complications 
and expense to analyze the cost of illness provide useful knowledge 
for health professionals and policy makers and this information are 
helpful for decision makers of the national health professionals for 
prioritizing research and fund allocations by indicating the 
inappropriate use of resources [13]. 
None of the persons with diabetes indicated that their cost is born 
by an insurance company or their employer. Almost all the cost is 
out of pocket from individual or family income. This is not exactly 
similar to some other studies, but Grover and colleagues reported 
that 95% of cost is met by patient and their families in India [22]. 
The total number of diabetic patients in Pakistan is 6.6 million with 
age group of 20 to 79 according to International diabetes federation 
(IDF). So if calculate the total economic burden of diabetes mellitus 
in Pakistan with average cost of diabetes management in Pakistan is 
rupees 5542. The total cost is Pakistan Rupees 36,577,200,000 per 
month which is tremendously high economic burden of diabetes in 
Pakistan. This estimated cost may be high or low as in this study the 
average cost is calculated and may be all patients not bear the all 
expense so their diabetes management cost is low, but on the other 
hand it is high then this value if add the cost of hospitalization, work 
days lost due to diabetes.  
The result of this study is alarming for Pakistani society and should 
take action to control this disease in Pakistan and try to minimize 
the economic burden of this disease. The further studies required in 
this field and to evaluate on yearly basis the economic loss due to 
diabetes mellitus in Pakistan and 5.5% patient in Pakistan bears 
Rs.4200 treatment cost of diabetes. 
Determining the cost of a specific disease is claimed to furnish useful 
information for health policy making and it is proved that such 
information can help nations to prioritize research funding and 
improve efficiency by indicating areas where inefficiencies may exist 
and savings could be made 
CONCLUSION 
In developing countries, the disease based economic studies are very 
rare and in Pakistan very few studies has previously been 
documented. The approximate calculation of these studies provides 
very helpful information related to the disease management cost 
and the impact that a society faces from such illness. 
The primary research can further need investigation in which cost 
effective intervention could be evaluated to decrease the economic 
burden of diabetes. In this study, there are some limitations, which 
would be considered before generating the results. First the 
inclusive criteria were restricted to outpatient and the 20 to 60 
years age group and the exclusive criteria consist of pregnant 
women, people having age of less than 20 years and those having 
an age of more than 60 years. This information is quite enough to 
make some suggestion and recommendation, for example an 
affordable and easily reachable health service is needed for all 
diabetic patients. 
Policy makers need to ensure efficient implementation of prevention 
programs at primary healthcare units and availability of cost 
effective and cheaper anti diabetic drugs to reduce the medication 
cost. It is the responsibility of the pharmaceutical company to 
produce improves quality and lower price drugs for the diabetic 
patients. Pharmaceutical companies should promote and allocate 
funds for the disease based research to know the financial burden of 
the disease to propose a better policy. It is important to understand 
and upgrade the current disease knowledge and best practices for 
better treatment of diabetes. 
Particularly this will help in developing preventive strategies to 
overcome the irrational prescribing by emphasizing rational use of 
drug and their benefit of decreasing economic cost to the patient and 
society. There is an urgent need that the authorities and public and 
private organizations to work closely for the reduction of the 
economic burden. 
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